Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03246321
Other study ID # NL60405.100.17
Secondary ID 2017-000927-29NT
Status Completed
Phase Phase 2
First received
Last updated
Start date October 1, 2017
Est. completion date October 1, 2019

Study information

Verified date October 2019
Source Catharina Ziekenhuis Eindhoven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC-OX) as a palliative monotherapy for patients with isolated unresectable colorectal peritoneal metastases.


Description:

Rationale: repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is known about its feasibility, safety, tolerability, efficacy, costs, and pharmacokinetics in this setting.

Objectives: to prospectively explore the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetic profile of repetitive ePIPAC-OX as a palliative monotherapy for isolated unresectable colorectal PM under controlled circumstances.

Study design: multicentre, open-label, single-arm, phase II study.

Setting: two Dutch tertiary referral hospitals for the surgical treatment of colorectal PM.

Study population: adults who have a World Health Organisation (WHO) performance status of 0 or 1, adequate organ functions, histologically or cytologically confirmed unresectable PM of a colorectal or appendiceal carcinoma, no systemic metastases, no symptoms of gastrointestinal obstruction, no contraindications for the planned intervention, and no previous pressurised intraperitoneal aerosol chemotherapy (PIPAC).

Intervention: instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled ePIPAC-OX (92 mg/m2 body-surface area [BSA]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)introduced.

Outcomes: the primary outcome is the number of patients with major toxicity (grade ≥3 according to the Common Terminology Criteria for Adverse Events v4.0) up to four weeks after the last procedure. Secondary outcomes are the environmental safety of ePIPAC-OX, procedure-related characteristics, the number of procedures in each patient and reasons for discontinuation, minor toxicity, organ-specific toxicity, postoperative complications, hospital stay, readmissions, quality of life, costs, progression-free survival, overall survival, and the radiological, histopathological, cytological, biochemical, and macroscopic tumour response. Atomic absorption spectrophotometry is used to measure concentrations of oxaliplatin in plasma, plasma ultrafiltrate, urine, ascites, PM, and normal peritoneum during and after ePIPAC-OX.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date October 1, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Eligible patients are adults who have:

- a World Health Organisation (WHO) performance status of =1;

- histological or cytological proof of PM of a colorectal or appendiceal carcinoma;

- unresectable disease determined by abdominal computed tomography (CT) and a diagnostic laparoscopy or laparotomy;

- adequate organ functions (haemoglobin =5.0 mmol/L, neutrophils =1.5 x 109/L, platelets =100 x 109/L, serum creatinine <1.5 x ULN, creatinine clearance =30 ml/min, and liver transaminases <5 x ULN);

- no symptoms of gastrointestinal obstruction;

- no radiological evidence of systemic metastases;

- no contraindications for oxaliplatin or 5-fluorouracil/leucovorin;

- no contraindications for a laparoscopy;

- no previous PIPAC-procedures.

Enrolled patients are excluded from the analyses in case they did not receive a first ePIPAC-OX, e.g.:

- due to systemic metastases on baseline thoracoabdominal CT, or;

- due to non-access during first ePIPAC-OX, or;

- due to resectable disease during first ePIPAC-OX.

Importantly, enrolment is allowed for patients with an unresected primary tumour (if asymptomatic) and for patients in various lines of palliative treatment, including patients who refuse, have not had, or do not qualify for first-line palliative systemic therapy. All potentially eligible patients are discussed by a multidisciplinary team. Enrolled patients are informed about the potential consequences of postponing or discontinuing standard palliative treatment by a medical oncologist prior to enrolment.

Study Design


Intervention

Combination Product:
repetitive ePIPAC-OX
Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area [BSA]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.

Locations

Country Name City State
Netherlands Catharina Hospital Eindhoven
Netherlands St. Antonius Hospital Nieuwegein

Sponsors (1)

Lead Sponsor Collaborator
Koen Rovers

Country where clinical trial is conducted

Netherlands, 

References & Publications (3)

Giger-Pabst U, Tempfer CB. How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures. J Gastrointest Surg. 2018 Dec;22(12):2187-2193. doi: 10.1007/s11605-018-3916-5. Epub 2018 Aug 21. — View Citation

Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017 May;104(6):669-678. doi: 10.1002/bjs.10521. Review. — View Citation

Tempfer C, Giger-Pabst U, Hilal Z, Dogan A, Rezniczek GA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. Arch Gynecol Obstet. 2018 Aug;298(2):243-257. doi: 10.1007/s00404-018-4784-7. Epub 2018 Jun 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Major toxicity Number of patients with Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade III-V, up to 4 weeks after the last ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Minor toxicity Number of patients with Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade II, up to 4 weeks after the last ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Organ-specific toxicity Number of patients that develops bone marrow, kidney, or liver function disorders, up to four weeks after the last ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Major postoperative complications Number of patients with Clavien-Dindo grade III-V postoperative complications, up to four weeks after the last ePIPAC Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Minor postoperative complications Number of patients with Clavien-Dindo grade II postoperative complications, up to four weeks after the last ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Hospital stay Number of days between ePIPAC-OX and initial discharge, up to four weeks after the last ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Readmissions Number of hospital admissions after initial discharge after ePIPAC-OX, up to four weeks after the last ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Radiological tumour response Number of patients with radiological response/stable disease/progression, based on central review of thoracoabdominal CT and diffusion-weighted MRI at baseline and four weeks after each ePIPAC-OX, performed by two independent radiologists blinded to clinical outcomes (classification not defined a priori) Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Histopathological tumour response Peritoneal Regression Grading Score (PRGS), based on central review of collected peritoneal biopsies during each ePIPAC-OX, performed by two independent pathologists blinded to clinical outcomes Expected (in case of three ePIPAC-OX): 12 weeks
Secondary Cytological tumour response Number of patients with positive/negative cytology, based on collected ascites or peritoneal washing cytology during each ePIPAC-OX Expected (in case of three ePIPAC-OX): 12 weeks
Secondary Macroscopic tumour response Peritoneal Cancer Index and ascites volume during each ePIPAC-OX Expected (in case of three ePIPAC-OX): 12 weeks
Secondary Biochemical tumour response Tumour marker value measured at baseline, each postoperative day, and four weeks after each ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Quality of life: EQ-5D-5L EQ-5D-5L at baseline and one and four weeks after each ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Quality of life: QLQ-C30 QLQ-C30 at baseline and one and four weeks after each ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Quality of life: QLQ-CR29 QLQ-CR29 at baseline and one and four weeks after each ePIPAC-OX Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Costs Costs of treatment, based on questionnaires (iMTA PCQ, iMTA MCQ) four weeks after each ePIPAC-OX, derived from the Dutch costing guidelines for health care research at the time of analysis Expected (in case of three ePIPAC-OX): 16 weeks
Secondary Progression-free survival Time between enrolment and clinical, radiological, or macroscopic progression, or death 24 months
Secondary Overall survival Time between enrolment and death 24 months
Secondary Environmental safety of ePIPAC-OX Platinum concentrations in the air of the operating room and on the surface of the operating room during ePIPAC-OX 1 week (measured only during the first three procedures in the study)
Secondary Pharmacokinetics Platinum concentrations in plasma and plasma ultrafiltrate (collected before ePIPAC-OX and 5, 10, 20, 30, 60, 120, 240, 360, and 1080 minutes after oxaliplatin injection), urine (collected before ePIPAC-OX and on postoperative days 1, 3, 5, and 7), and two pieces of normal peritoneum and two peritoneal metastases collected during each ePIPAC-OX. Expected (in case of three ePIPAC-OX): 13 weeks
Secondary Procedure-related characteristics: intraoperative complications Number of procedures with intraoperative complications determined during each ePIPAC-OX Expected (in case of three ePIPAC-OX): 12 weeks
Secondary Procedure-related characteristics: adhesions Zühlke score determined during each ePIPAC-OX Expected (in case of three ePIPAC-OX): 12 weeks
Secondary Procedure-related characteristics: operating time Operating time in minutes determined during each ePIPAC-OX Expected (in case of three ePIPAC-OX): 12 weeks
Secondary Procedure-related characteristics: blood loss Blood loss in minutes determined during each ePIPAC-OX Expected (in case of three ePIPAC-OX): 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A